Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Combining conventional therapy with immunotherapy: A risky business?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 30-day mortality in frail patients undergoing cardiac surgery: the results of the frailty in cardiac surgery (FICS) copenhagen study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chronic pain after bilateral thoracotomy in lung transplant patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. De første 25 år med lungetransplantation i Danmark: Statusartikel

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Colorectal cancer (CRC) patients have increased levels of human neutrophil peptides 1-3 (HNP1-3) in tumour tissue and plasma. The aim is to study whether the amount of HNP1-3 in tumour and plasma from CRC patients correlate with Dukes' stages A-D. The amount of HNP1-3 in tumour tissue, normal colonic mucosa, and plasma was determined with mass spectrometry. Plasma levels of HNP1-3 were determined with enzyme-linked immuno-sorbent assay (ELISA). The amount of HNP1-3 determined with mass spectrometry was increased in tumours compared to normal colonic tissue in CRC patients in Dukes' stage A-D, whereas HNP1-3 in plasma was only elevated in Dukes' stage D compared to healthy individuals. HNP1-3 plasma concentration determined with ELISA was increased in Dukes' stages C and D, but not in A and B. It is concluded that HNP1-3 is a potential marker for prognostic assessment, surveillance of patients, and monitoring chemotherapy in CRC patients with advanced disease.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume42
Issue number17
Pages (from-to)3057-64
Number of pages8
ISSN0959-8049
DOIs
Publication statusPublished - Nov 2006

    Research areas

  • Adult, Biomarkers, Tumor, Colorectal Neoplasms, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, alpha-Defensins, Journal Article, Research Support, Non-U.S. Gov't

ID: 49497129